Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel Syndrome With Constipation
Links shared publicly online about this topic.
- 874total visits
Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel Syndrome With Constipation
View full resource at medicalnewstoday.com
Tags: Constipation, IBS, Disease and Condition, Pharma, Phase 3 Clinical Trial, Clinical Trial, Forest Laboratories
Most Recently Shared on September 14, 2010 at 4:00 pm By:
Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel Syndrome... http://mnt.to/3JHY
Also Shared By:
Ironwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome With Constipation
medicalnewstoday.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with ir” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2011 at 2:24 pm By:
Irritable Bowel Syndrome OW Health
Ironwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome... http://bit.ly/jDiZNV
Ironwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome With Constipation
medicalnewstoday.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with ir” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2011 at 12:05 pm By:
Ironwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome With ... http://mnt.to/3VsD
Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results fr” View full resource at businesswire.com
Most Recently Shared on May 4, 2011 at 2:20 pm By:
Irritable Bowel Syndrome OW Health
Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome... http://bit.ly/kxSgYY
Positive results from linaclotide Phase 3 trial in patients with IBS-C
news-medical.net — “Almirall, S.A. and Ironwood Pharmaceuticals, Inc. today announced positive top-line results from a 26-week pivotal Phase 3 clinical trial assessing the efficacy and safety of once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation (IBS-C).” View full resource at news-medical.net
Most Recently Shared on November 2, 2010 at 9:51 am By:
Irritable Bowel Syndrome OW Health
Positive results from linaclotide Phase 3 trial in patients with IBS-C: Almirall, S.A. and Ironwood Pharmaceutical... http://bit.ly/can7Ui
Ironwood and Forest Announce Positive Linaclotide Results from Second Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from a 26-week Phase” View full resource at businesswire.com
Most Recently Shared on November 1, 2010 at 9:50 pm By:
Irritable Bowel Syndrome OW Health
Ironwood and Forest Announce Positive Linaclotide Results from Second Phase 3 Trial in Patients with Irritable Bow... http://bit.ly/9l93VK
Almirall and Ironwood Announce Positive Results from the Second Phase 3 Trial of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “Almirall and Ironwood announced positive top-line results from a 26-week pivotal Phase 3 clinical trial assessing the efficacy and safety of linacloti” View full resource at businesswire.com
Most Recently Shared on November 1, 2010 at 9:50 pm By:
Irritable Bowel Syndrome OW Health
Almirall and Ironwood Announce Positive Results from the Second Phase 3 Trial of Linaclotide in Patients with ...:... http://bit.ly/aSdcnP
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable Bowel Syndrome with Constipation - Drugs.com MedNews
drugs.com — “Top-line results of the phase 3 study with linaclotide show that both primary and main secondary endpoints were met and was well tolerated. Irritable bowel synd” View full resource at drugs.com
Most Recently Shared on September 17, 2010 at 2:20 pm By:
Inflammatory Bowel Syndrome OW Health
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable B... http://bit.ly/ak4b8r
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable Bowel Syndrome with Constipation - Drugs.com MedNews
drugs.com — “Top-line results of the phase 3 study with linaclotide show that both primary and main secondary endpoints were met and was well tolerated. Irritable bowel synd” View full resource at drugs.com
Most Recently Shared on September 16, 2010 at 1:15 pm By:
Drugs and Devices OW OW Health
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irrita... http://bit.ly/aDsObr #drug
Almirall, Ironwood announce positive results from phase 3 trial with linaclotide in patients with IBS with constipation - Clinical Trials
pharmabiz.com — “Almirall, S.A. and Ironwood Pharmaceuticals, Inc. announced positive top?line results from a phase 3 clinical trial assessing the efficacy and safety of a once?daily dosing of linaclotide 266 mcg” View full resource at pharmabiz.com
Most Recently Shared on September 15, 2010 at 7:29 am By:
Irritable Bowel Syndrome OW Health
Almirall, Ironwood announce positive results from phase 3 trial with linaclotide in patients with IBS with constip... http://bit.ly/bCnYxs
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation - News Press Release | PharmiWeb.com
pharmiweb.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, lin” View full resource at pharmiweb.com
Most Recently Shared on September 14, 2010 at 1:28 pm By:
Irritable Bowel Syndrome OW Health
Press Release: Forest Laboratories Inc. & Ironwood Pharmaceuticals Inc. Posted on:14 Sep 10 http://bit.ly/91v3Rw
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation - Drugs.com MedNews
drugs.com — “Top-line Results Show Trial Met All Primary and Secondary Endpoints Sep 13, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) and Forest Laboratories, Inc. (N” View full resource at drugs.com
Most Recently Shared on September 14, 2010 at 1:08 pm By:
Drugs and Devices OW OW Health
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel... http://bit.ly/c32M1e #drug
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C). Analyses of the data indicate clinically meaningful and statistically significant improvement was achieved for linaclotide-treated pa” View full resource at businesswire.com
Most Recently Shared on September 14, 2010 at 1:26 am By:
Irritable Bowel Syndrome OW Health
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Synd... http://bit.ly/dpTPsH
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “BARCELONA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced positive top-line results from a Phase 3 clinical trial assessing the efficacy and safety of a once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation. The two co-primary endpoints required by the European Medicines Agency (EMA) were met in this study, showing statistical significance and clinically relevant improvem” View full resource at businesswire.com
Most Recently Shared on September 14, 2010 at 1:23 am By:
Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable B... http://bit.ly/9BgTDe
Advertisement
Health Line
@IBSline
#IBS Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel ... http://sns.ly/JZQ43
1 year ago...